Segment Reporting - Schedule of reportable segment net income (loss) (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||||
| Segment Reporting [Line Items] | ||||||||||
| Grant revenue | $ 736 | $ 0 | $ 1,094 | $ 0 | ||||||
| Operating Expenses | 22,009 | 24,881 | 43,274 | 52,117 | ||||||
| Impairment of long-lived assets | 5,807 | 0 | 5,807 | 0 | ||||||
| Gain on sale of VOWST Business | 25,000 | 185 | 25,000 | 52,366 | ||||||
| Net income (loss) | 4,581 | $ (19,913) | (19,855) | $ 32,682 | (15,332) | 12,827 | ||||
| Operating Segments [Member] | ||||||||||
| Segment Reporting [Line Items] | ||||||||||
| Grant revenue | 736 | 0 | 1,094 | 0 | ||||||
| R&D personnel-related (including stock-based compensation) | 3,680 | 6,084 | 9,600 | 12,202 | ||||||
| G&A personnel-related (including stock-based compensation) | 2,671 | 3,725 | 5,962 | 7,898 | ||||||
| Professional fees | 1,442 | 2,155 | 3,156 | 5,335 | ||||||
| Facility-related and other | 2,948 | 4,373 | 6,013 | 8,908 | ||||||
| Impairment of long-lived assets | 5,807 | 0 | 5,807 | 0 | ||||||
| Gain on sale of VOWST Business | [1] | (25,000) | (185) | (25,000) | (52,366) | |||||
| Other segment (income) expense | [2] | (367) | (3,149) | (1,266) | (7,356) | |||||
| Live Biotherapeutics Platform [Member] | Operating Segments [Member] | ||||||||||
| Segment Reporting [Line Items] | ||||||||||
| Operating Expenses | 4,875 | 5,808 | 11,408 | 10,931 | ||||||
| SER-155 [Member] | Operating Segments [Member] | ||||||||||
| Segment Reporting [Line Items] | ||||||||||
| Operating Expenses | $ 99 | $ 1,044 | $ 746 | $ 1,621 | ||||||
| ||||||||||
| X | ||||||||||
- Definition Facility related and other. No definition available.
|
| X | ||||||||||
- Definition Gain loss on sale of business from continuing operations. No definition available.
|
| X | ||||||||||
- Definition General and administrative personnel expense. No definition available.
|
| X | ||||||||||
- Definition Research and development personnel expense. No definition available.
|
| X | ||||||||||
- Definition Revenue from Grant. No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|